Skip to main navigation

Overview
News & Events
- Press Releases
- Events and Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Financials
Governance
IR Resources
- Email Alerts
- Contact IR

Press Releases

Press Releases

Recent Releases

September 6, 2022

Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

August 15, 2022

Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

August 3, 2022

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Press Releases

Year

March 30, 2022

Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future

March 24, 2022

Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update

March 21, 2022

Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors

March 21, 2022

Athira Pharma to Participate in Two Upcoming Investor Conferences

March 20, 2022

Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress

March 17, 2022

Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022

March 14, 2022

Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress

March 2, 2022

Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

February 22, 2022

Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

February 22, 2022

Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page
Last page

Displaying 21 - 30 of 81

SIGN UP FOR EMAIL ALERTS

CONTACT IR

Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011

Main line: (866) 725-0930
Local number: (425) 620-8501
info@athira.com

© Athira Pharma, Inc. All rights reserved.